Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Forbes

New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know

New Pancreatic Cancer Drug Nearly Doubles Survival. Here’s What Patients Should Know
ShareXFacebook

A new pancreatic cancer drug called daraxonrasib cut the risk of death by 60% in a Phase 3 trial. What it is, how it works, side effects and when it could reach patients.

F

Source

Forbes

Read full article at Forbes

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement